Ropes & Gray Advises Cambrex in its Acquisition of Halo Pharma
Ropes & Gray advised Cambrex Corporation, a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, in its agreement to acquire Halo Pharma, a leading dosage form Contract Development and Manufacturing Organization, for approximately $425 million. Halo Pharma is majority owned by funds managed by the private investment firm SK Capital Partners. The transaction, announced on July 23, is expected to close during the third quarter of 2018, subject to customary closing conditions.
Halo Pharma provides drug product development and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile and non-sterile ointments. The company operates two state-of-the-art facilities located in Whippany, N.J. and Montreal, Canada.
The Ropes & Gray team was led by securities & public companies associate Tom Fraser, securities & public companies partner Paul Kinsella, tax partner David Saltzman, benefits partner Adam Stella, IP transactions partner Mark Bellomy and life sciences partner Albert Cacozza.